Loading market dashboard
Thermo Fisher Scientific Inc.
TMOHealthcareNYSEUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
West Pharmaceutical said on Monday it appointed former Thermo Fisher Scientific executive Michel Lagarde as its top boss, effective August 31, succeeding longtime chief Eric Green.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today expanded its suite of Thermo Scientific™ Orbitrap™ mass spectrometry platforms, AI-enabled software and integrated workflows at the American Society for Mass Spectrometry (ASMS) Conference. Across research, biopharma and applied testing, scientists face increasingly complex samples, expanding data sets and greater pressure to deliver confident answers faster. Thermo Fisher helps solve that.
Thermo Fisher (TMO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
On May 28, 2026, Thermo Fisher Scientific Inc (TMO) shares rose 6.8% today, now trading at $487.22. The stock's performance remains volatile with a 52-week rang
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced the Thermo Scientific™ Orbitrap™ Tribrid™ Apex and Thermo Scientific™ Orbitrap™ Excedion™ mass spectrometers will be showcased at the American Society for Mass Spectrometry (ASMS) Conference. As scientific discovery expands into more complex applications—from advanced proteomics and multiomics to biologics and genetic medicines—researchers and drug developers face inc.
On May 26, 2026, we present a DCF analysis for Thermo Fisher Scientific Inc (TMO). The stock has experienced a mixed performance recently, with a year-to-date d
Thermo Fisher Scientific Inc. (TMO) Analyst/Investor Day Transcript
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on July 15, 2026, to shareholders of record as of June 15, 2026. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Our Mission is to enable our customers to make the world healthier.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, hosted its Investor Day today. Chairman and Chief Executive Officer Marc N. Casper and members of the senior leadership team highlighted the company's industry leadership and the essential role of its best-in-class products and services to customers around the world. "Our customers value Thermo Fisher as their trusted partner,” said Marc N. Casper, chairman and chief executive office.
Jefferies, an investment banking and capital management firm, has updated its ‘Franchise Picks' list, which features the company's highest-conviction ‘Buy' rated stocks.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the opening of a new bioanalytical and biomarker laboratory in Gothenburg, Sweden, located within GoCo Health Innovation City. This new facility expands the company's global bioanalytical capabilities to support pharmaceutical and biotechnology customers across all phases of drug development. With state-of-the-art instrumentation and Good Laboratory Practice (GLP) capabilities, the la.
ROCHESTER, N.Y.--(BUSINESS WIRE)--Nalgene Outdoor today introduces the Fresh Flow™ straw bottle, a new addition to its reusable bottle collection designed to give fans more ways to hydrate without sacrificing the simplicity, durability, and approachable price points they expect from a Nalgene bottle. The result is a slim 24-oz bottle paired with a new interchangeable Fresh Flow cap that lets fans sip from a straw, chug from a spout, or swap the cap onto other Nalgene bottles they already own. T.
On May 11, 2026, we present a discounted cash flow (DCF) analysis for Thermo Fisher Scientific Inc (TMO). The company has experienced a challenging price perfor
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, earned a Leader designation among contract research organizations (CROs) in the 2026 ISG Provider Lens™ Life Sciences Digital Services report, underscoring the company's continued investment in digital innovation across the clinical development continuum. The recognition highlights the strength of Thermo Fisher's PPD™ clinical research business, which is recognized for its capabilities in clinic.
Examine Thermo Fisher's (TMO) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy developers scale manufacturing with precise control, flexibility, and regulatory readiness. As cell therapies move from early research into clinical development and commercialization, manufacturers face increasing pressure to transition from static culture systems to s.
On May 04, 2026, we present a detailed DCF analysis for Thermo Fisher Scientific Inc (TMO), a company that has experienced a price decline of 18.9% year-to-date
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the opening of its flagship U.S. Bioprocess Design Center (BDC) at the company's Plainville, Mass., site, expanding the facility to support customers in developing and scaling biologics. The new center brings together advanced bioproduction capabilities and hands-on collaboration to help customers accelerate process development and bring transformative therapies to patients faste.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, will hold its 2026 Investor Day on Wednesday, May 20, 2026, starting at 9:00 a.m. ET in New York City. The format will feature presentations by members of Thermo Fisher Scientific's senior management team and conclude with a Q&A session. The live webcast of the presentation can be accessed via the Investors section of our website, https://ir.thermofisher.com. A replay of the webc.
Thermo Fisher Scientific has struck a deal to sell its microbiology business to European private-equity firm Astorg for about $1.075 billion.
Thermo Fisher Scientific said on Monday it has agreed to sell its microbiology business to a pan-European private equity firm Astorg for about $1.08 billion, consisting of cash and a $50 million seller note.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has signed a definitive agreement to sell its microbiology business to Astorg, a leading pan-European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. The microbiology business provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food.
On April 27, 2026, we delve into the DCF analysis for Thermo Fisher Scientific Inc (TMO), a company currently facing a challenging price performance with a year
Comerica Bank lessened its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 4.1% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,308 shares of the medical research company's stock after selling 3,787 shares during the period.
Concurrent Investment Advisors LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 131.4% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 10,603 shares of the medical research company's stock after buying an additional
AEGON ASSET MANAGEMENT UK Plc reduced its stake in Thermo Fisher Scientific Inc. (NYSE: TMO) by 2.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 58,972 shares of the medical research company's stock after selling 1,644 shares during
The real brain computer interface opportunity isn't in the headlines. These 10 stocks are building the systems that make it possible.
Thermo Fisher Scientific experienced a sharp post-Q1 selloff despite beating sales and EPS expectations and raising full-year guidance. Inorganic growth from recent acquisitions, notably Clario, contributed materially to raised EPS guidance and overall revenue outlook. Short-term headwinds in government/academic spending and diagnostics are not expected to derail Thermo's long-term growth strategy, supported by reshoring and AI adoption.
Thermo Fisher Scientific Inc. (NYSE:TMO) on Thursday reported first-quarter 2026 adjusted earnings of $5.44 per share, beating the street view of $5.24.
Thermo Fisher Scientific Inc. (TMO) Q1 2026 Earnings Call Transcript
Shares of Thermo Fisher Scientific Inc (NYSE:TMO, XETRA:TN8) were down more than 7.5% on Thursday after investors weighed a stronger-than-expected quarterly profit against muted underlying growth and a still-cautious outlook despite an upgraded full-year revenue forecast. The life sciences tools and services company reported adjusted earnings per share of $5.44 for the first quarter of fiscal 2026, beating analyst expectations of $5.25.
TMO beats Q1 EPS and revenue estimates with steady growth, yet shares slip 4% in pre-market after results and mixed segment performance.
Although the revenue and EPS for Thermo Fisher (TMO) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.44 per share, beating the Zacks Consensus Estimate of $5.2 per share. This compares to earnings of $5.15 per share a year ago.
Shares of Thermo Fisher Scientific Inc (NYSE:TMO, XETRA:TN8) were down more than 7.5% on Thursday after investors weighed a stronger-than-expected quarterly...
Thermo Fisher Scientific on Thursday reported first-quarter profit and revenue above Wall Street estimates, as growth in its laboratory products and biopharma services business helped offset softness in analytical instruments and specialty diagnostics.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026. First Quarter Highlights First quarter revenue grew 6% to $11.01 billion. First quarter GAAP diluted earnings per share (EPS) grew 11% to $4.43. First quarter adjusted EPS grew 6% to $5.44. Delivered excellent performance in the first quarter, demonstrating the strength of our proven growth strategy, the.
Caprock Group LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 21.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,304 shares of the medical research company's stock after acquiring an additional
Boston Trust Walden Corp lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) by 9.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,973 shares of the medical research company's stock after purchasing an additional
AE Wealth Management LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE: TMO) by 92.4% during the undefined quarter, according to its most recent filing with the SEC. The institutional investor owned 5,257 shares of the medical research company's stock after selling 63,724 shares during the period. AE Wealth Management LLC's holdings
Thermo Fisher Scientific (TMO) remains a high-quality, stable business, but its stock is currently overvalued relative to its growth outlook. TMO reported FY25 revenue growth of 3.9% and EPS growth of 7.3%, with management guiding for 6–8% adjusted EPS growth in FY26. Despite solid fundamentals and resilient end-markets, valuation multiples near 30x earnings/free cash flow appear stretched unless double-digit growth resumes.
Evaluate the expected performance of Thermo Fisher (TMO) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
On April 20, 2026, we present a detailed DCF analysis for Thermo Fisher Scientific Inc (TMO). The stock has shown a price performance of +6.2% over the past wee
Atlantic Edge Private Wealth Management LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 24.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,281 shares of the medical research company's stock after purchasing an additional 1,248
We are actively monitoring Meta Platforms' social and data privacy risks and believe the company has made progress on strengthening its policies and enforcement. We believe the market is underestimating the durability of Edwards' transcatheter aortic valve replacement franchise and the opportunity for its transcatheter mitral and tricuspid therapies. We exited our position in Workday to bring the portfolio's software exposure closer to market weight.
Farther Finance Advisors LLC lifted its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 24.1% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 9,542 shares of the medical research company's stock after purchasing an additional 1,854 shares during
Baxter Bros Inc. trimmed its position in Thermo Fisher Scientific Inc. (NYSE: TMO) by 6.9% during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 19,223 shares of the medical research company's stock after selling 1,414 shares during the period.
Thermo Fisher (TMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Thermo Fisher heads into Q1 earnings with Life Sciences Solutions growth in focus, as bioproduction strength and new innovations may drive results.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the Applied Biosystems™ PowerFlex™ Thermal Cycler, a next-generation polymerase chain reaction (PCR) instrument designed to help deliver enhanced flexibility, precise thermal performance and improved productivity for modern molecular biology laboratories. Building on the trusted legacy of Applied Biosystems™ instruments, this solution is designed to help laboratories run complex.
Assetmark Inc. grew its position in Thermo Fisher Scientific Inc. (NYSE: TMO) by 22.9% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 37,654 shares of the medical research company's stock after buying an additional 7,023 shares during the period. Assetmark Inc.'s holdings in Thermo Fisher
Consolidated Investment Group LLC reduced its holdings in Thermo Fisher Scientific Inc. (NYSE: TMO) by 21.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,730 shares of the medical research company's stock after selling 3,000 shares during the quarter. Thermo
Border to Coast Pensions Partnership Ltd boosted its stake in Thermo Fisher Scientific Inc. (NYSE: TMO) by 17.8% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 200,442 shares of the medical research company's stock after acquiring an additional 30,245 shares during the quarter. Thermo
Thermo Fisher Scientific (NYSE: TMO - Get Free Report) is anticipated to announce its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect the company to announce earnings of $5.25 per share and revenue of $10.8606 billion for the quarter. Investors may review the information on the company's upcoming Q1 2026 earning
Bingham Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE: TMO) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 1,002 shares of the medical research company's stock, valued at approximately $581,000. Several other hedge funds
Thermo Fisher Scientific (NYSE: TMO - Get Free Report) and Sysmex (OTCMKTS:SSMXY - Get Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, profitability and analyst recommendations. Dividends Thermo Fisher Scientific pays an annual dividend
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced a strategic data collaboration with HealthVerity, a leading real-world data (RWD) marketplace, to enhance data-driven clinical development and evidence generation for biopharma sponsors. Through the agreement, Thermo Fisher's PPD™ clinical research business will gain enterprise-level access to HealthVerity's TaXOnomy® claims dataset, representing more than 270 million de-identified pa.
On April 13, 2026, we delve into the DCF analysis for Thermo Fisher Scientific Inc (TMO), a company that has experienced a mixed price performance recently, wit
